Of 882 participants enrolled, 128 had PD-L1 CPS < 1 and 373 had CPS 1-19. For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 ...

Subgroup analysis revealed a pronounced effect among patients receiving MAC. In this cohort, 6-month grade 2-4 GFS was 35.7% with placebo vs 60.7% with ustekinumab (OR 2.78 for failure; 80% CI, 1.19-6 ...

An analysis of reports from phase III trials (published between 2011 and 2013) investigating patients with solid tumours found widespread failings in both the conduct and reporting of subgroup ...

The values of the subgroup-variable, which is specified in the chart statement, indicate how the observations in the input data set (a DATA=, HISTORY=, or TABLE= data set) are arranged into rational ...

Medulloblastoma is a highly malignant paediatric brain tumour classified into four biologically and clinically distinct molecular subgroups 1. The present clinical approach to medulloblastoma involves ...

Myosteatosis on computed tomography as a predictor of therapeutic response to CDK4/6 inhibitors plus aromatase inhibitors in patients with advanced breast cancer. Subgroup OS HR (95% CI) OS p-value ...

One of the most recognized features of No Child Left Behind is subgroup analysis, which shifted attention from the average performance of a school to the performance of specific populations within a ...

These subgroup analyses add to the existing evidence of bempedoic acid as an effective treatment for the reduction of cardiovascular risk. MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe GmbH ...

Subgroup analyses are an important part of the analysis of a comparative clinical trial. However, they are commonly overinterpreted 1 – 4 and can lead to further research that is misguided or, worse, ...

Nerandomilast slowed FVC decline in US IPF patients compared to placebo, with a favorable safety profile and tolerability. The FIBRONEER-IPF trial was a double-blind, placebo-controlled study ...